Trial · NCT03377790
Cantharidin Application in Molluscum Patients-1
NCT03377790, Phase 3, Completed, Verrica Pharmaceuticals Inc.; results first posted 2021-12-14
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Cantharidin Application in Molluscum Patients-1. Trials, record NCT03377790. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03377790
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cantharidin Application in Molluscum Patients-1
- NCT number
- NCT03377790
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 266 participants, actual
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Conditions
- Molluscum Contagiosum
- Interventions
- VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
- First posted
- 2017-12-19
- Last updated
- 2022-01-11
- Results first posted
- 2021-12-14
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | Day 1 (Baseline and new) compared to Day 84 (EOS) | Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). |
| Secondary | Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | Day 1 (Baseline and new) compared to Day 63 | Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. |
| Secondary | Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | Day 1 (Baseline and new) compared to Day 42 | Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. |
| Secondary | Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | Day 1 (Baseline and new) compared to Day 21 | Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. |
| Other | Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. | Baseline to Day 84 (EOS) | Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: * 3: Very much (or Prevented School, Question 7 only) * 2: Quite a lot * 1: Only a little * 0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome). |
| Other | Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit | Day 1 (Baseline) compared to Day 84 (EOS) | Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. |
| Other | Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Day 1 (Baseline) compared to Day 84 (EOS) | Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. |
| Other | Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Day 1 (Baseline) compared to Day 84 (EOS) | Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. |
| Other | Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Day 1 (Baseline) compared to Day 84 (EOS) | Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. |
| Other | Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject. | Days 1, 21, 42, 63 and 84 (EOS). | Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions. |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | Day 1 (Baseline and new) compared to Day 84 (EOS) | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | Day 1 (Baseline and new) compared to Day 63 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | Day 1 (Baseline and new) compared to Day 42 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | Day 1 (Baseline and new) compared to Day 21 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. | Baseline to Day 84 (EOS) | ITT Population (Subjects 4-16 years of age) | units on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit | Day 1 (Baseline) compared to Day 84 (EOS) | ITT Population | percentage of change in wart count | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Day 1 (Baseline) compared to Day 84 (EOS) | ITT Population | change in wart count | MEAN |
| OTHER_PRE_SPECIFIED | Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Day 1 (Baseline) compared to Day 84 (EOS) | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Day 1 (Baseline) compared to Day 84 (EOS) | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject. | Days 1, 21, 42, 63 and 84 (EOS). | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | VP-102 | 74 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | Placebo | 19 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | VP-102 | 51 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | Placebo | 18 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | VP-102 | 33 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | Placebo | 10 | Participants | ||
| Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | VP-102 | 18 | Participants | ||
| Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | Placebo | 4 | Participants | ||
Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. | VP-102 | -2.1 | Standard Deviation 2.70 | units on a scale | |
Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. | Placebo | -2.7 | Standard Deviation 3.46 | units on a scale |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | VP-102 | 160 | |
| Overall Study | STARTED | Placebo | 106 | |
| Overall Study | COMPLETED | VP-102 | 150 | |
| Overall Study | COMPLETED | Placebo | 100 | |
| Overall Study | NOT COMPLETED | VP-102 | 10 | |
| Overall Study | NOT COMPLETED | Placebo | 6 |
Source ClinicalTrials.gov
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application site pruritus | Skin and subcutaneous tissue disorders | VP-102 | 104 | 161 | |
| other | Application site pruritus | Skin and subcutaneous tissue disorders | Placebo | 38 | 104 | |
| other | Application site erythema | Skin and subcutaneous tissue disorders | VP-102 | 69 | 161 | |
| other | Application site erythema | Skin and subcutaneous tissue disorders | Placebo | 30 | 104 | |
| other | Application site scab | Skin and subcutaneous tissue disorders | VP-102 | 62 | 161 | |
| other | Application site scab | Skin and subcutaneous tissue disorders | Placebo | 25 | 104 | |
| other | Application site discolouration | Skin and subcutaneous tissue disorders | VP-102 | 54 | 161 | |
| other | Application site discolouration | Skin and subcutaneous tissue disorders | Placebo | 18 | 104 | |
| other | Application site dryness | Skin and subcutaneous tissue disorders | VP-102 | 24 | 161 | |
| other | Application site dryness | Skin and subcutaneous tissue disorders | Placebo | 11 | 104 |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | VP-102 | 0 | 161 |
| Total, all-cause mortality | Placebo | 0 | 104 |
| Total, other adverse events | VP-102 | 159 | 161 |
| Total, other adverse events | Placebo | 76 | 104 |
| Total, serious adverse events | VP-102 | 0 | 161 |
| Total, serious adverse events | Placebo | 1 | 104 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons9
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Trial comparisons |
| VP-102 vs Placebo: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | Trial comparisons |
| VP-102 vs Placebo: Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject. | Trial comparisons |
| VP-102 vs Placebo: deaths from any cause | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | Trial comparisons |
| VP-102 vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03377790
GET https://conductscience.org/api/trials/v1/NCT03377790/events?page=2